PMID- 31405675
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20211204
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 13
IP  - 4
DP  - 2019 Jul-Aug
TI  - Impaired function of fibroblast growth factor 23 / Klotho protein axis in 
      prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk.
PG  - 2549-2556
LID - S1871-4021(19)30405-9 [pii]
LID - 10.1016/j.dsx.2019.07.018 [doi]
AB  - The discovery of clear molecular mechanisms of early cardiac and vascular 
      complications in patients with prediabetes and known diabetes mellitus are core 
      element of stratification at risk with predictive model creation further. 
      Previous clinical studies have shown a pivotal role of impaired signaling axis of 
      fibroblast growth factor 23 (FGF23), FGF23 receptor isoforms and its co-factor 
      Klotho protein in cardiovascular (CV) complications in prediabetes and diabetes. 
      Although there were data received in clinical studies, which confirmed a 
      causative role of altered function of FGF-23/Klotho protein axis in manifestation 
      of CV disease in prediabetes and type 2 diabetes mellitus (T2DM), the target 
      therapy of these diseases directing on improvement of metabolic profiles, 
      systemic and adipokine-relating inflammation by beneficial restoring of 
      dysregulation in FGF-23/Klotho protein axis remain to be not fully clear. The aim 
      of the review was to summarize findings regarding the role of impaired 
      FGF-23/Klotho protein axis in developing CV complications in patients with 
      prediabetes and type 2 diabetes mellitus. It has been elucidated that elevated 
      levels of FGF-23 and deficiency of Klotho protein in peripheral blood are 
      predictors of CV disease and CV outcomes in patients with (pre) diabetes, while 
      predictive values of dynamic changes of the concentrations of these biomarkers 
      require to be elucidated in detail in the future.
CI  - Copyright (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Berezin, Alexander E
AU  - Berezin AE
AD  - Internal Medicine Department, State Medical University, Ministry of Health of 
      Ukraine, Zaporozhye, 69035, Ukraine. Electronic address: aeberezin@gmail.com.
FAU - Berezin, Alexander A
AU  - Berezin AA
AD  - Internal Medicine Department, Medical Academy of Post-Graduate Education, 
      Ministry of Health of Ukraine, Zaporozhye, 69096, Ukraine.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190709
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Biomarkers)
RN  - 0 (FGF23 protein, human)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 7Q7P4S7RRE (Fibroblast Growth Factor-23)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - EC 3.2.1.31 (Klotho Proteins)
SB  - IM
MH  - Biomarkers/*metabolism
MH  - Cardiovascular Diseases/*diagnosis/etiology/metabolism
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Fibroblast Growth Factor-23
MH  - Fibroblast Growth Factors/*metabolism
MH  - Glucuronidase/*metabolism
MH  - Humans
MH  - Klotho Proteins
MH  - Prediabetic State/*complications
MH  - Prognosis
MH  - Risk Factors
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Diabetes mellitus
OT  - Fibroblast growth factor 23
OT  - Klotho protein
OT  - Metabolism
OT  - Prediabetes
EDAT- 2019/08/14 06:00
MHDA- 2020/01/07 06:00
CRDT- 2019/08/14 06:00
PHST- 2019/06/12 00:00 [received]
PHST- 2019/07/08 00:00 [accepted]
PHST- 2019/08/14 06:00 [entrez]
PHST- 2019/08/14 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
AID - S1871-4021(19)30405-9 [pii]
AID - 10.1016/j.dsx.2019.07.018 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2019 Jul-Aug;13(4):2549-2556. doi: 
      10.1016/j.dsx.2019.07.018. Epub 2019 Jul 9.